BRPI0417469B8 - biphenyl carboxamides substituted with n-aryl piperidine, pharmaceutical composition comprising them and process for preparing them - Google Patents

biphenyl carboxamides substituted with n-aryl piperidine, pharmaceutical composition comprising them and process for preparing them

Info

Publication number
BRPI0417469B8
BRPI0417469B8 BRPI0417469A BRPI0417469A BRPI0417469B8 BR PI0417469 B8 BRPI0417469 B8 BR PI0417469B8 BR PI0417469 A BRPI0417469 A BR PI0417469A BR PI0417469 A BRPI0417469 A BR PI0417469A BR PI0417469 B8 BRPI0417469 B8 BR PI0417469B8
Authority
BR
Brazil
Prior art keywords
preparing
pharmaceutical composition
aryl piperidine
compounds
biphenyl carboxamides
Prior art date
Application number
BRPI0417469A
Other languages
Portuguese (pt)
Inventor
Theodorus Maria Linders Joannes
Meerpoel Lieven
Viellevoye Marcel
Original Assignee
Janssen Phamaceutica N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Phamaceutica N V filed Critical Janssen Phamaceutica N V
Publication of BRPI0417469A publication Critical patent/BRPI0417469A/en
Publication of BRPI0417469B1 publication Critical patent/BRPI0417469B1/en
Publication of BRPI0417469B8 publication Critical patent/BRPI0417469B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

N-aryl piperidine substituted biphenylcarboxamides compounds of formula (I) methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes.
BRPI0417469A 2003-12-09 2004-12-06 biphenyl carboxamides substituted with n-aryl piperidine, pharmaceutical composition comprising them and process for preparing them BRPI0417469B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03104601 2003-12-09
EP03104601.4 2003-12-09
PCT/EP2004/053280 WO2005058824A2 (en) 2003-12-09 2004-12-06 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprote in b

Publications (3)

Publication Number Publication Date
BRPI0417469A BRPI0417469A (en) 2007-04-10
BRPI0417469B1 BRPI0417469B1 (en) 2019-06-25
BRPI0417469B8 true BRPI0417469B8 (en) 2021-05-25

Family

ID=34684566

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417469A BRPI0417469B8 (en) 2003-12-09 2004-12-06 biphenyl carboxamides substituted with n-aryl piperidine, pharmaceutical composition comprising them and process for preparing them

Country Status (19)

Country Link
US (1) US8772494B2 (en)
EP (1) EP1694644B1 (en)
JP (1) JP4790626B2 (en)
KR (1) KR101125120B1 (en)
CN (1) CN100548985C (en)
AT (1) ATE548350T1 (en)
AU (1) AU2004299295B2 (en)
BR (1) BRPI0417469B8 (en)
CA (1) CA2547243C (en)
EA (1) EA009081B1 (en)
ES (1) ES2383179T3 (en)
HK (1) HK1100559A1 (en)
IL (1) IL176171A (en)
NO (1) NO337251B1 (en)
NZ (1) NZ546964A (en)
SG (1) SG149001A1 (en)
UA (1) UA83510C2 (en)
WO (1) WO2005058824A2 (en)
ZA (1) ZA200604718B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948629A1 (en) * 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
CN102851291B (en) 2006-04-03 2016-03-09 斯特拉有限责任公司 Comprise the pharmaceutical composition of anti-miRNA antisense oligonucleotides
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
CA2681406A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
ES2463665T3 (en) 2007-10-04 2014-05-28 Stella Aps Combination treatment for the treatment of hepatitis C virus infection
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
JP5773535B2 (en) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ Pharmaceutical composition for the treatment of HCV patients unresponsive to interferon
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
EP3591054A1 (en) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting pcsk9

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Polyarylcarboxamides useful as lipid lowering agents
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Lipid lowering biphenulcarboxamides
GB0109287D0 (en) * 2001-04-12 2001-05-30 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
UA79300C2 (en) * 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion

Also Published As

Publication number Publication date
CA2547243C (en) 2012-10-23
BRPI0417469A (en) 2007-04-10
EP1694644B1 (en) 2012-03-07
US8772494B2 (en) 2014-07-08
AU2004299295A1 (en) 2005-06-30
EP1694644A2 (en) 2006-08-30
SG149001A1 (en) 2009-01-29
US20070099934A1 (en) 2007-05-03
WO2005058824A3 (en) 2005-10-27
CN1890217A (en) 2007-01-03
WO2005058824A2 (en) 2005-06-30
HK1100559A1 (en) 2007-09-21
EA200601120A1 (en) 2006-10-27
JP4790626B2 (en) 2011-10-12
IL176171A (en) 2013-08-29
AU2004299295B2 (en) 2010-07-15
NO20063103L (en) 2006-09-05
NZ546964A (en) 2009-03-31
CA2547243A1 (en) 2005-06-30
BRPI0417469B1 (en) 2019-06-25
IL176171A0 (en) 2006-10-05
JP2007513921A (en) 2007-05-31
KR20060111628A (en) 2006-10-27
ATE548350T1 (en) 2012-03-15
CN100548985C (en) 2009-10-14
UA83510C2 (en) 2008-07-25
ZA200604718B (en) 2007-10-31
KR101125120B1 (en) 2012-03-21
EA009081B1 (en) 2007-10-26
ES2383179T3 (en) 2012-06-18
NO337251B1 (en) 2016-02-22

Similar Documents

Publication Publication Date Title
NO20063103L (en) N-aryl-piperidine-substituted biphenyl carboxamides
BRPI0512974A (en) New Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases
BR0212008A (en) Use of a compound or a salt, solvate or prodrug thereof, a pharmaceutical composition, a compound or a salt, solvate or prodrug thereof and process for the preparation thereof
BR0309546A (en) A compound, a pharmaceutical composition comprising the same, a process for its preparation and use and a method for the prophylactic or therapeutic treatment of type II diabetes.
BRPI0519106A2 (en) compounds, their use, process for their manufacture, pharmaceutical compositions, method for the treatment and / or prophylaxis of diseases that are associated with dpp-iv
CY1112398T1 (en) CYROLOXYL PYROLYLIDINE SUBSTITUTES AS 11-B-HYDROXYSTEROHYDROHYDROHOUSE INHIBITIONS 1
BR0315047A (en) Compound, pharmaceutical composition comprising the same, process for preparing the pharmaceutical composition, use of the compounds, method of treatment and process for the preparation of the compound
EA200870475A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID-DEGYDROGENASE TYPE 1
ATE419848T1 (en) CYCLOALKYL-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE 1
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
DK2021336T3 (en) 11-beta-hydroxysteroid dehydrogenase-1 inhibitors
BRPI0409454A (en) compounds, process for their manufacture, pharmaceutical compositions comprising them, method for the treatment and / or prophylaxis of diseases that are associated with the glucagon receptor and their use
BRPI0517032A (en) compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treating and / or preventing diseases and using such compounds
BRPI0511466B8 (en) peptide vasopressin receptor agonists, pharmaceutical composition comprising said agonists and use thereof
BRPI0416287A (en) compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for the treatment and / or prevention of diseases that are modulated by accß inhibitors and their use
BRPI0606502A2 (en) compounds; process for the manufacture of compounds; pharmaceutical compositions; method for treating or preventing diseases that are associated with modulation of h3 receptors; method for treating or preventing obesity in a human or animal; method of treating or preventing type ii diabetes in a human or animal and uses of compounds
BR0208688A (en) Lipid Decreasing Biphenyl Carboxamides
JO2478B1 (en) 4-(Aminomethyl)-Piperidine Benzamides As 5ht4-Antagonists
BRPI0409069A (en) chemical compounds
BRPI0510679A (en) compounds, process for their manufacture, pharmaceutical compositions containing them, method for the treatment and / or prophylaxis of diseases that are associated with cb1 receptor modulation and use of such compounds
BRPI0514099A (en) pharmaceutical compositions, compounds, process for their manufacture, method for the therapeutic and / or prophylactic treatment of diseases and use of the compounds
BRPI0415497A (en) process compound for its preparation, pharmaceutical composition comprising the same, use of a compound and method for treating type II diabetes
CY1107097T1 (en) 5HT4-COMPETITIVE BENZAMIDES 4- (AMINOMETHYL) - Piperidine
JO2529B1 (en) N-aryl piperidine substituted biphenylcarboxamides
DE602004029888D1 (en) Hydroxycarbonylphenyl substituierte 4-(aminomethyl)-piperidinbenzamide als 5ht4-antagonisten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2699 DE 27-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.